Model-informed dose optimization of mycophenolic acid in pediatric kidney transplant patients

Heida, Astrid

DOI: https://doi.org/10.1007/s00228-024-03743-0

2024-08-19

European Journal of Clinical Pharmacology

Abstract:We aimed to develop and evaluate a population PK model of mycophenolic acid (MPA) in pediatric kidney transplant patients to aid MPA dose optimization.

pharmacology & pharmacy

What problem does this paper attempt to address?

Population pharmacokinetics of mycophenolic acid and dose optimisation in adult Chinese kidney transplant recipients

Kaisaner Rexiti,Xuehui Jiang,Ying Kong,Xu Chen,Hong Liu,Hongwei Peng,Xiaohua Wei

DOI: https://doi.org/10.1080/00498254.2023.2287168

2023-01-01

Xenobiotica

Abstract:1. This study aimed to establish a population pharmacokinetic (PPK) model of mycophenolic acid (MPA), quantify the effect of clinical factors and pharmacogenomics of MPA, and optimise the dosage for adult kidney transplant recipients.2. One-hundred and four adult renal transplant patients were enrolled. The PPK model was established using the Phoenix (R) NMLE software and the stepwise methods were filtered for significant covariates. Monte Carlo simulations were performed to optimise the dosage regimen.3. A two-compartment model with first-order absorption and elimination (including lag time) provided a more accurate description of MPA pharmacokinetics. Serum albumin (ALB) significantly affected the central apparent clearance (CL/F), whereas post-transplant time and creatinine clearance were associated with a central apparent volume of distribution (V/F). The estimated population values obtained by the final model were 17.5 L/h and 93.97 L for CL/F and V/F, respectively. Simulation results revealed that larger mycophenolate mofetil doses are required as the ALB concentration decreases. This study established a PPK model of MPA and validated it using various methods. ALB significantly affected CL/F and recommended optimal dose strategies were given based on the final model. These results provide a reference for the personalised therapy of MPA for kidney transplant patients.
Pharmacokinetics of Mycophenolic Acid in Chinese Kidney Transplant Patients

Lu Xiao-yang,Huang Hong-feng,Sheng-Tu Jian-zhong,Liu Jian

DOI: https://doi.org/10.1007/bf02840998

2005-01-01

Abstract:To assess the influence of cyclosporin A (CsA) and tacrolimus (FK506) on mycophenolic acid (MPA) and correlation analysis of the pharmacokinetic parameters and patient characteristics, clinical outcome in Chinese kidney transplant recipients, the pharmacokinetics of 1000 mg mycophenolate mofetil (MMF) twice daily was measured by high-performance liquid chromatography (HPLC). PKS (Pharmaceutical Kinctics Software) 1.0.2 software package was used for the calculation of pharmacokinetic parameters. The meanCmax,tmax, and AUC(0–12) were (21.88±10.52) μg/ml, (1.20±0.95) h, and (52.546±13.215) μg·h/ml, respectively. The level of AUC(0–12) in the FK506 group was significantly higher than that in the CsA group. MPA appeared not to be affected by renal function. MPA AUC(0–12) showed statistically significant difference according to the patient's gender.
Pharmacokinetics Study of Mycophenolate Mofetil in Renal Transplantation Patients

LU Xiao-yang,HUANG Hong-feng,HUANG Ming-zhu,SHENG-TU Jian-zhong

DOI: https://doi.org/10.3321/j.issn:1001-2494.2005.16.014

2005-01-01

Abstract:OBJECTIVE To determine the steady state pharmacokinetics of mycophenolic acid (MPA), the active metabolite, after an oral administration of mycophenolate mofetil (MMF) in the kidney transplant patients. METHODS 22 Kidney transplant subjects (14 men and 8 women) were administered with a single dose of 1.0 g MMF every 12 hours and serum MPA concentrations were measured by high perfor-mance liquid chromatography (HPLC) using solid-phase extraction. The 3P87 pharmaceutical kinetics software was used for the calculation of pharmacokinetic parameters. RESULTS The means of tmax,ρmax, area under the curve (AUC0→12), mean residence time (MRT). and clearance (CL) were (1.27±1.063)h, (20.83±11.71)mg·L-1, (49.81±13.57) mg·h·L-1, (3.37±0.73)h, and (17.97±9.02) L·h-1, respectively. CONCLUSION An inter-individual variability is obtained in MPA pharmacokinetic parameters, which is consistent with the result reported previously.
Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant

Yuki Suzuki,Noriko Matsunaga,Takahiko Aoyama,Chika Ogami,Chihiro Hasegawa,Satofumi Iida,Hideto To,Takashi Kitahara,Yasuhiro Tsuji

DOI: https://doi.org/10.1111/cts.70097

2024-12-06

Clinical and Translational Science

Abstract:The pharmacokinetics (PKs) of mycophenolic acid (MPA) exhibit considerable complexity and large variability. We developed a population pharmacokinetic (popPK) model to predict the complex PK of MPA by examining an absorption model. Forty‐two patients who had undergone renal transplantation were included in this study. popPK analysis, incorporating several absorption models, was performed using the nonlinear mixed‐effects modeling program NONMEM. The MPA area under the concentration‐time curve at 0–12 h (AUC0–12) was simulated using the final model to calculate the recommended dose. The PK of MPA was adequately described using a two‐compartment model incorporating sequential zero‐ and first‐order absorption with lag time. Total body weight, renal function (RF), and posttransplantation day (PTD) were included as covariates affecting MPA PK. The final model estimates were 7.56, 11.6 L/h, 104.0 L, 17.3 L/h, 169.0 L, 0.0453, 0.283, and 1.95 h for apparent nonrenal clearance, apparent renal clearance, apparent central volume of distribution, apparent intercompartmental clearance, apparent peripheral volume of distribution, absorption half‐life, lag time, and duration of zero‐order absorption, respectively. Simulation results showed that a dose regimen of 500–1000 mg twice daily is recommended during the early posttransplantation period. However, dose reduction could be required with increased PTD and decreased RF. The complex PK of MPA was explained using an absorption model. The developed popPK model can provide useful information regarding individual dosing regimens based on PTD and RF.

medicine, research & experimental
Population pharmacokinetic and dose optimization of mycophenolic acid in children with anti-neutrophilic cytoplasmic antibody-associated nephritis

Ziwei Li,Yidie Huang,Hong Xu,Zhiping Li

DOI: https://doi.org/10.1007/s00228-021-03265-z

2022-01-22

European Journal of Clinical Pharmacology

Abstract:PurposeAnti-neutrophilic cytoplasmic antibody (ANCA)–associated vasculitis is a rare autoimmune disease. Mycophenolic acid (MPA) is widely used for ANCA-associated nephritis (AAN) but with large pharmacokinetic variability. This study aims to investigate clinical factors impacting MPA disposition in pediatric AAN.MethodsWe retrospectively collected 391 MPA concentrations from 25 children diagnosed with AAN. A population pharmacokinetic model was developed to explore the potential effects of demographics and biochemical covariates on MPA. Monte Carlo simulations were performed to optimize dosage regimen.ResultsMPA pharmacokinetics best fitted a two-compartment model with first-order absorption and linear elimination. The pharmacokinetic parameters for Ka, CL/F, Vc/F, Vp/F, and Q/F were 0.45 h−1, 9.86 L/h, 19.69 L, 408.32 L, and 23.01 L/h. Dosage form significantly affected drug absorption. CL/F significantly decreased with increasing cystatin C, while decreasing with myeloperoxidase. Cystatin C was superior to serum creatinine in predicting apparent clearance of MPA. A dose regimen of 650 mg/m2 twice daily was required to achieve target exposure in children with normal renal function and no inflammation. The combined effects of myeloperoxidase concentration and renal function resulted in a sixfold range of MPA dose.ConclusionThis was the first study of MPA population pharmacokinetic model in children with AAN. Myeloperoxidase was not only a biomarker of AAN, but also an inflammatory factor to impact drug CL. The influence of renal function and underlying diseases on drug metabolism should be fully considered in personalized medication for AAN.

pharmacology & pharmacy
Cystatin C and myeloperoxidase based mycophenolic acid dosage optimization in pediatric anti-neutrophilic cytoplasmic antibody-associated nephritis

Ziwei Li,Yidie Huang,Hong Xu,Zhiping Li

DOI: https://doi.org/10.22541/au.162391331.12750392/v1

2021-06-17

Abstract:Aims Mycophenolic acid (MPA) is typically used for anti-neutrophilic cytoplasmic antibody associated nephritis (AAN) but with large individual variability of pharmacokinetics. This study aims to investigate clinical factors impacting MPA disposal so as to simulate dosage regimen in pediatric AAN. Methods We conducted a retrospective study in 25 children with AAN treated with MPA. A population pharmacokinetic model was developed to explore the effects of demographics and biochemical covariates on MPA. Monte Carlo simulations were performed to optimize dosage regimens. Results A total of 391 MPA concentrations from 25 patients were analyzed. MPA pharmacokinetics best fitted a two-compartment model with first-order absorption and linear elimination. The pharmacokinetic parameters for Ka, CL, Vc, Vp, and Q were 0.45 h-1, 9.86 L/h, 19.69 L, 408.32 L and 23.01 L/h, respectively. Dosage form significantly affected drug absorption. CL significantly decreased with increasing cystatin C, while with decreasing myeloperoxidase. Cystatin C was superior to serum creatinine in predicting CL of MPA. A dose of 650 mg/m2 was required to achieve the target exposure in children with normal renal function and no inflammation. Dose of MPA in patients with renal failure was almost 1/3 that of normal kidney function. The combined effects of myeloperoxidase and renal function resulted in a 6-fold range in MPA dose. Conclusions Myeloperoxidase was not only a biomarker of AAN, but also an inflammatory factor to impact drug CL. The influence of renal function and underlying diseases on drug metabolism should be fully considered in personalized medication for AAN children.
Population Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Children after Renal Transplantation and Initial Dosage Recommendation Based on Body Surface Area.

Guangfei Wang,Qiaofeng Ye,Yidie Huang,Hong Xu,Zhiping Li

DOI: https://doi.org/10.1155/2022/1881176

IF: 2.809

2022-01-01

Computational and Mathematical Methods in Medicine

Abstract:Objective. Enteric-coated mycophenolate sodium (EC-MPS) is widely used in renal transplant recipients. There is a lack of study on the pharmacokinetics of this drug in children. This study is aimed at developing a population pharmacokinetic model of mycophenolic acid in children who were treated with EC-MPS after renal transplantation and to recommend initial dosage. Methods. Pediatric patients who had undergone renal transplantation and received EC-MPS were included. Data on demographic characteristics, biochemical tests, blood routine examinations, mycophenolic acid plasma concentrations, dosing amount and frequency of EC-MPS, and coadministered medications were retrospective collected from June 2018 to August 2019. Nonlinear mixed effect modeling methods were adopted to develop a population pharmacokinetic model with the data above. Additional data from September 2019 to July 2020 were used to validate the model. Simulations under different dosage regimen were conducted to evaluate the percentage of target attainment (PTA, AUC0-12h 30–60 mg·h/L). Results. A total of 96 pediatric patients aged at 13.3 (range 4.3–18.0) years were included in the modeling group. Data from 32 patients aged at 13.0 (range 3.6–18.3) years were used to validate the model. A one-compartment model with a double extravascular absorption was developed. Body surface area (BSA) was added as a covariate. Simulations showed that for different dosing regimens, the highest percentage of target attainment is around 50%. The best dosing regimen is 180 mg every 48 hours for patients with BSA of 0.22–0.46 m2, 180 mg every 24 hours with BSA of 0.47–0.67 m2, 180 mg every 24 hours with BSA of 0.68–0.96 m2, 360 mg every 24 hours with BSA of 0.97–1.18 m2, 540 mg every 24 hours with BSA of 1.19–1.58 m2, and 360 mg every 12 hours with BSA of 1.59–2.03 m2. Conclusion. BSA could affect the area under curve of mycophenolic acid with the administration of EC-MPS. Considering the inflexibility of the dosage form, future development of smaller amount per tablet suitable for younger children with BSA<1.19 m2 is warranted.
Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

Xi Yao,Hongfeng Huang,Chunchun Wei,Ying Chen,Wenhan Peng,Wenqing Xie,Jianghua Chen

DOI: https://doi.org/10.1097/ftd.0000000000000170

2015-01-01

Therapeutic Drug Monitoring

Abstract:Background:Mycophenolic acid (MPA), a potent immunosuppressant, is widely used in solid organ transplantations. This study aimed to investigate the pharmacokinetics of enteric-coated mycophenolate sodium (EC-MPS) in Chinese adult renal allograft recipients and to generate optimal model equations for estimation of the MPA area under the concentration-time curve from 0 to 12 hours (AUC(0-12 h)), using a limited sampling strategy (LSS).Methods:Serial blood samples were collected over 12 hours from 38 recipients of a primary living-related donor kidney graft treated with EC-MPS, tacrolimus, and corticosteroid. MPA concentrations were evaluated using an enzyme-multiplied immunoassay technique. The LSSs were developed and validated by multiple regression analysis using a 2-group method (test group, n = 19; validation group, n = 19).Results:The best algorithms obtained from the test group were the following: 15.09 + 1.05 x C-1.5 + 1.8 x C-4 + 4.18 x C-6 (for 3 time points, r(2) = 0.902) and 10.44 + 0.7 x C-1 + 1.22 x C-2 + 1.75 x C-4 + 4.36 x C-6 (for 4 time points, r(2) = 0.941). When these algorithms were tested in the validation group, there were no significant differences in prediction errors.Conclusions:LSSs using time points of 1.5, 4, and 6 hours or 1, 2, 4, and 6 hours after dose provide effective and reliable estimations of the MPA AUC(0-12 h) in Chinese renal allograft recipients treated concomitantly with EC-MPS and tacrolimus during the early posttransplantation phase.
Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients

Zi-Cheng Yu,Pei-Jun Zhou,Xiang-Hui Wang,Bressolle Françoise,Da Xu,Wei-Xia Zhang,Bing Chen

DOI: https://doi.org/10.1038/aps.2017.115

Abstract:Mycophenolate mofetil (MMF) is an important immunosuppressant used in renal transplantation, and mycophenolic acid (MPA) is the active component released from the ester prodrug MMF. The objective of this study was to investigate the population pharmacokinetics of mycophenolic acid (MPA) following oral administration of MMF in Chinese adult renal transplant recipients and to identify factors that explain MPA pharmacokinetic variability. Pharmacokinetic data for MPA and covariate information were retrospectively collected from 118 patients (79 patients were assigned to the group for building the population pharmacokinetic model, while 39 patients were assigned to the validation group). Population pharmacokinetic data analysis was performed using the NONMEM software. The pharmacokinetics of MPA was best described by a two-compartment model with a first-order absorption rate with no lag time. Body weight and serum creatinine level were positively correlated with apparent clearance (CL/F). The polymorphism in uridine diphosphate glucuronosyltransferase gene, UGT2B7, significantly explained the interindividual variability in the initial volume of distribution (V1/F). The estimated population parameters (and interindividual variability) were CL/F 18.3 L/h (34.2%) and V1/F 27.9 L (21.3%). The interoccasion variability was 13.7%. These population pharmacokinetic data have significant clinical value for the individualization of MMF therapy in Chinese adult renal transplant patients.
Pk/Pd Study Of Mycophenolate Mofetil In Children With Systemic Lupus Erythematosus To Inform Model-Based Precision Dosing

Yewei Chen,Li Sun,Hong Xu,Min Dong,Tomoyuki Mizuno,Alexander A Vinks,Hermine I Brunner,Yifan Li,Zhiping Li

DOI: https://doi.org/10.3389/fphar.2020.605060

IF: 5.6

2020-01-01

Frontiers in Pharmacology

Abstract:Objectives: To evaluate the mycophenolic acid [MPA, the active form of mycophenolate mofetil (MMF)] pharmacokinetic parameters in relation to clinical response to identify target exposure ranges in pediatric patients with systemic lupus erythematosus (SLE).Methods: This was a retrospective study using pharmacokinetic data collected in 67 pediatric patients aged 4-18 years with SLE. Target MPA exposures for effective inhibition of SLE activity (as measured by SLE disease Activity Index (SLEDAI), active SLE was defined as a SLEDAI score of >= 6, and a controlled disease was defined as a SLEDAI score of <= 4) were assessed by receiver operating characteristic (ROC) curve and logistic regression. Exposure-response models were developed to quantitatively describe the relationship between SLEDAI score and AUC(0-12) or C-trough, respectively.Results: The MPA AUC(0-12) in patients with active SLE was significantly lower than that in patients with inactive SLE. ROC analysis revealed that an AUC(0-12) threshold of 39 mu g h/ml or a C-trough of 1.01 mu g/ml was associated with the lowest risk of active SLE. Logistic regression analysis revealed that an AUC(0-12) of less than 34 mu g h/ml or a C-trough of less than 1.2 mu g/ml probably is associated with active SLE. The results of the exposure-response modeling also indicated that an AUC(0-12) less than 32 mu g h/ml or a C-trough less than 1.1 mu g/ml was associated with suboptimal clinical outcome. An AUC(0-12) above 50 mu g h/ml or a C-trough above 1.7 ug/ml was associated with disease control.Conclusion: Both AUC(0-12) and C-trough of MPA are predictive of the likelihood of active SLE in pediatric patients receiving MMF. An individualized dosing regimen of MMF, with a target AUC(0-12) or C-trough, should be considered for SLE patients.
Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients

Dong-Dong Wang,Xiao Chen,Meng Fu,Qing-Shan Zheng,Hong Xu,Zhi-Ping Li

DOI: https://doi.org/10.1080/00498254.2019.1631505

2020-01-01

Xenobiotica

Abstract:1. Numerous tacrolimus population pharmacokinetic (PPK) models in pediatric liver transplantation patients have been established to define an optimal dose schedule. However, the applicability of extrapolating these PPK models to our clinical center remains unknown. The goals of the present study was to evaluate model external predictiveness and establish a new model applicable to traditional therapeutic drug monitoring data. 2. Published PPK models were collected from the literature and assessed using our real-world dataset including 41 pediatric liver transplantation patients via the individual prediction error method. The establishment of a new model was characterized using non-linear mixed-effects modeling. 3. Nine published pediatric liver transplantation PPK models were identified, three of which could be applied to our real-world dataset. However, these models were dissatisfactory in terms of individual prediction error and hence, inadequate for extrapolation. Finally, a new model applicable to our real-world dataset was established as follows: CL/F = 22.9 x (WT/70)(0.75) x (1 - WZ x 0.264) x (1 - FCZ x 0.338) x (1 + ASPI x 0.281) x (POD/41)(0.0486) L/h; V/F = 906 x (WT/70) L. Where WT, WZ, FCZ, ASPI and POD were weight, Wuzhi capsule, fluconazole, aspirin and post-transplantation day, respectively. In conclusion, published models were inadequate for application to our real-world dataset. The present study produced a new model applicable to our real-world study data.
Mycophenolic Acid Exposure Prediction Using Machine Learning

Jean‐Baptiste Woillard,Marc Labriffe,Jean Debord,Pierre Marquet

DOI: https://doi.org/10.1002/cpt.2216

2021-04-06

Abstract:Therapeutic drug monitoring of mycophenolic acid (MPA) based on area under the curve (AUC) is well-established and machine learning (ML) approaches could help to estimate AUC. The aim of this work is to estimate the AUC of MPA in organ transplant patients using extreme gradient boosting (Xgboost R package) ML models. A total of 12,877 MPA AUC from 0 to 12 hours (AUC<sub>0-12 h</sub> ) requests from 6,884 patients sent to our Immunosuppressant Bayesian Dose Adjustment expert system (https://abis.chu-limoges.fr) for AUC estimation and dose recommendation based on MPA concentrations measured at least at three sampling times (~ 20 minutes, 1 and 3 hours after dosing) were used to develop two ML models based on two or three concentrations. Data were split into a training set (75%) and a test set (25%) and the Xgboost models in the training set with the lowest root mean squared error (RMSE) in a 10-fold cross-validation experiment were evaluated in the test set and in 4 independent full-pharmacokinetic (PK) datasets from renal or heart transplant recipients. ML models based on two or three concentrations, differences between these concentrations, relative deviations from theoretical times of sampling, presence of a delayed absorption peak, and five covariates (dose, type of transplantation, associated immunosuppressant, age, and time between transplantation and sampling) yielded accurate AUC estimation performances in the test datasets (relative bias < 5% and relative RMSE < 20%) and better performance than MAP Bayesian estimation in the four independent full-PK datasets. The Xgboost ML models described allow accurate estimation of MPA AUC<sub>0-12 h</sub> and can be used for routine exposure estimation and dose adjustment and will soon be implemented in a dedicated web interface.

pharmacology & pharmacy
Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients

Dongdong Wang,Xiao Chen,Hong Xu,Zhiping Li

DOI: https://doi.org/10.1080/00498254.2019.1601791

2019-04-25

Xenobiotica

Abstract:1. Several tacrolimus population pharmacokinetic (PPK) models in hematopoietic stem cell transplantation (HSCT) patients have been set up to recommend an optimal dosage schedule. However, the PPK model of Chinese pediatric HSCT patients has not been reported. The study is to investigate whether published PPK models of HSCT patients can be used to simulate Chinese pediatric HSCT patients and establish the tacrolimus PPK model of Chinese pediatric HSCT patients.2. Published PPK models were collected from the literature and assessed using Chinese pediatric HSCT patients via the individual prediction error method. The establishment of tacrolimus PPK model in Chinese pediatric HSCT patients was characterized with nonlinear mixed-effects modeling (NONMEM).3. Three published HSCT PPK models were identified, two of which could be applied to our external dataset. However, these models were dissatisfactory in terms of individual prediction error and, hence, inadequate for extrapolation. Finally, a new tacrolimus PPK model in Chinese pediatric HSCT patients was established. Based on the simulation results of our model, new initial dosage suggestions were recommended. In conclusion, the tacrolimus PPK model in Chinese pediatric HSCT patients was presented and the model could be used to predict individualized dosing regimens in children with HSCT.

pharmacology & pharmacy,toxicology
Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co‐treated with tacrolimus: A population analysis

Chun‐lan Yang,Chang‐cheng Sheng,Gui‐yi Liao,Yong Su,Li‐juan Feng,Quan Xia,Zheng Jiao,Du‐juan Xu

DOI: https://doi.org/10.1111/jcpt.13488

2021-07-26

Journal of Clinical Pharmacy and Therapeutics

Abstract:What is known and objectiveMycophenolate mofetil, an ester prodrug of mycophenolic acid (MPA), is widely used to prevent graft rejection after kidney transplantation. The pharmacokinetic (PK) of MPA has been extensively studied, which revealed a high degree of variability. An integrated population PK (PopPK) model of MPA and its main metabolite mycophenolic acid glucuronide (MPAG) was developed using the adult patients who underwent kidney transplant and were administered oral mycophenolate mofetil combined with tacrolimus. MethodsIn total, 917 MPA and 740 MPAG concentrations in191 adult patients were analysed via nonlinear mixed-effects modelling. The concentration-time data were adequately described using a chain compartment model, including central and peripheral compartments for MPA and a central compartment for MPAG. Stepwise forward inclusion and backward elimination procedures were used to investigate the effects of genetic polymorphisms, including in UGT1A8, UGT1A9, UGT2B7, ABCB1, ABCC2, ABCG2, SLCO1B1, SLCO1B3, and HNF1α. Results and discussionThese genetic polymorphisms in metabolic enzymes and transporters have no obvious impact on the PK of MPA in adult patients who underwent kidney transplant and were co-treated with tacrolimus. The post-transplant time, serum albumin, and creatinine clearance were identified as significant covariates affecting the PK of MPA and MPAG, which should be considered in the clinical use of mycophenolate mofetil. What is new and conclusionWe established a PopPK model of MPA and MPAG in Chinese adult patients who underwent kidney transplant and were co-treated with tacrolimus. Genetic polymorphisms in metabolic enzymes and transporters showed no obvious impact on MMF PK. A model-informed dosing strategy was proposed by the established model, and MMF dose adjustment should be based on ALB levels and the post-transplantation time.

pharmacology & pharmacy
Population pharmacokinetics and dosing regimen optimisation of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients.

Dongdong Wang,Xiao Chen,Hong Xu,Zhiping Li

DOI: https://doi.org/10.1080/00498254.2019.1601791

2020-01-01

Xenobiotica

Abstract:1. Several tacrolimus population pharmacokinetic (PPK) models in hematopoietic stem cell transplantation (HSCT) patients have been set up to recommend an optimal dosage schedule. However, the PPK model of Chinese pediatric HSCT patients has not been reported. The study is to investigate whether published PPK models of HSCT patients can be used to simulate Chinese pediatric HSCT patients and establish the tacrolimus PPK model of Chinese pediatric HSCT patients. 2. Published PPK models were collected from the literature and assessed using Chinese pediatric HSCT patients via the individual prediction error method. The establishment of tacrolimus PPK model in Chinese pediatric HSCT patients was characterized with nonlinear mixed-effects modeling (NONMEM). 3. Three published HSCT PPK models were identified, two of which could be applied to our external dataset. However, these models were dissatisfactory in terms of individual prediction error and, hence, inadequate for extrapolation. Finally, a new tacrolimus PPK model in Chinese pediatric HSCT patients was established. Based on the simulation results of our model, new initial dosage suggestions were recommended. In conclusion, the tacrolimus PPK model in Chinese pediatric HSCT patients was presented and the model could be used to predict individualized dosing regimens in children with HSCT.
An integrated sampling strategy for therapeutic mycophenolic acid monitoring in lung transplant recipients

Laneshia K Tague,Hephzibah Anthony,Noha N Salama,Ramsey R Hachem,Brian F Gage,Andrew E Gelman

DOI: https://doi.org/10.1016/j.healun.2024.09.007

2024-09-16

Abstract:Background: Mycophenolic Acid (MPA) is the most used anti-proliferative in lung transplantation, but its pharmacokinetic (PK) variability has precluded therapeutic drug monitoring. Both genetic and clinical factors have been implicated in MPA variability. This study aimed to integrate genetic and clinical factors with PK measurements to quantify MPA exposure. Methods: We performed 12-hour pharmacokinetic analysis on 60 adult lung transplant recipients maintained on MPA for immunosuppression. We genotyped a SLCO1B3 polymorphisms previously associated MPA metabolism and collected relevant clinical data. We calculated area under the curve (AUC0-12) and performed univariate linear regression analysis to evaluate its association with genetic, clinical, and pharmacokinetic variables. We performed lasso regression analysis to create final AUC estimation tools. Results: PK-only measurements obtained 2, 3, and 8 hours after MPA administration (C2, C3, and C8) were strongly associated with MPA AUC0-12 (R267%, 67% and 68% respectively). Clinical and genetic factors associated with MPA AUC0-12 included the MPA dose (p = 0.001), transplant diagnosis (p = 0.015), SLCO1B3 genotype (p = 0.049), and body surface area (p = 0.050). The best integrated single-sampling strategy included C2 and achieved an R2 value of 80%. The best integrated limited-sampling strategy included C0, C0.25, and C2 and achieved an R2 value of 90%. Conclusions: An integrated limited sampling strategy (LSS) for MPA allows increased accuracy in prediction of MPA AUC0-12 compared to PK-only modeling. Validation of this model will allow for clinically feasible MPA therapeutic drug monitoring and help advance precision management of MPA.
245.5: Efficacy and Safety of an Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplant Recipients in China: A Prospective Cohort Study

Wenqing Xie,Wenhan Peng,Zhechi He,Junhao Lv,Wenhua Lei,Rending Wang,Hongfeng Huang,Jianyong Wu,Jianghua Chen

DOI: https://doi.org/10.1097/01.tp.0000886120.75939.63

2022-01-01

Transplantation

Abstract:Introduction: Previous study showed the standard dose of immunosuppressants enteric-coated mycophenolate sodium (EC-MPS) might result in unsatisfactory control rate of effective blood concentration and improvable acute rejection rate. This prospective cohort study was designed to evaluate the efficacy and safety of an intensified dosing regimen of EC-MPS in de novo kidney transplant recipients in China. Methods: This prospective cohort study enrolled patients underwent de novo renal transplantation from 2015.6 to 2018.9. Participants were divided into the intensified-dose (week 1: 2160 mg/day; week 2: 1440 mg/day; followed by 720-1080 mg/day) and standard-dose (week 1: 1440 mg/day; week 2: 1080 mg/day; followed by 720-1080 mg/day) groups. Sub-group were analyzed based on mycophenolic acid (MPA)-area under the concentration (AUC): achieved group (defined as patients whose MPA AUC is equal or beyond 40 mg.h/L within Day 7) and under exposure group (defined as patients whose MPA AUC is below 40 mg.h/L within Day 7). The primary endpoints were 12-month-biopsy-proven acute rejection (BPAR), graft and patient survival rates. safety were also assessed. The study was followed up 3 years. Results: A total of 128 patients were included, with 65 and 63 patients in the intensified-dose group and standard-dose group, respectively. The 12-month-BPAR incidence was numerically lower in the intensified-dose group than standard-dose group (4.6% vs. 9.5%, p=0.320). The rate of patients achieving target mycophenolic acid (MPA)-area under the concentration (AUC) was significantly higher in the intensified-dose group (87.5% vs. 69.8%, p=0.015) (Table 1) than standard-dose group, and patients achieving target MPA-AUC had a significantly lower 3-month-BPAR incidence (1.0% vs. 11.1%, p=0.03) (Table 2). patient and graft survival rates at 36 months between the intensified-dose and standard-dose groups was 98.5% vs. 100.0% and 98.5% vs. 100.0%, respectively. The 36-month- de novo donor-specific antibody (dnDSA) positive incidence rates was numerically lower in the intensified-dose group than standard-dose group (1.5% vs. 6.3%, p=0.204). In addition, delayed graft function, treatment failure, serum creatine levels, eGFRs and infection incidence had no significant differences between the two groups (all p>0.05) (Figure 1). The incidence rates of infection were similar in both groups (29.2% vs. 33.3%, p=0.617). No additional safety concerns related to intensified dosing of EC-MPS. Conclusion: Intensified dosing of EC-MPS results in a numerically lower incidence of 12-month-BPAR and lower positive incidence of dnDSA with 36 months follow up. Intensified dosing could help achieve target therapeutic blood concentration of EC-MPS, that showed significantly lower BPAR and no more infection incidence increased and might further improve long-term prognosis in Chinese de novo kidney transplantation recipients.
Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools

Yannick Hoffert,Nada Dia,Tim Vanuytsel,Robin Vos,Dirk Kuypers,Johan Van Cleemput,Jef Verbeek,Erwin Dreesen

DOI: https://doi.org/10.1007/s40262-024-01414-y

2024-09-22

Clinical Pharmacokinetics

Abstract:Tacrolimus is an immunosuppressant commonly administered after solid organ transplantation. It is characterized by a narrow therapeutic window and high variability in exposure, demanding personalized dosing. In recent years, population pharmacokinetic models have been suggested to guide model-informed precision dosing of tacrolimus. We aimed to provide a comprehensive overview of population pharmacokinetic models and model-informed precision dosing software modules of tacrolimus in all solid organ transplant settings, including a simulation-based investigation of the impact of covariates on exposure and target attainment.

pharmacology & pharmacy
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study

Lu Zhang,Lizhi Chen,Xiaohong Liu,Zhijun Huang,Yifan Zheng,Kejing Tang,Xiaoyun Jiang,Pan Chen

DOI: https://doi.org/10.1093/rheumatology/keae264

2024-09-01

Abstract:Objectives: Mycophenolic acid (MPA) is recommended for lupus nephritis (LN) treatment, but with large inter-individual variability in pharmacokinetics (PK). The aim of this study is to reveal the relationship between MPA exposure and disease response and adverse drug reactions in pediatric LN patients. Method: This was a population-based observational cohort study. A total of 86 pediatric LN patients treated with mycophenolate mofetil (MMF) for induction therapy were enrolled. The area-under the concentration-time curve (AUC) was calculated using MPA concentrations according to a limited sampling strategy. Receiver operating characteristic analysis was performed to assess the MPA-AUC threshold values. The cumulative incidence of renal remission and inactive systemic lupus erythematosus (SLE) over time was evaluated by Kaplan-Meier's analysis. Results: MPA-AUC was identified as an independent factor associated with renal remission and lupus activity at 6 and 12 months after MMF treatment, and the improved renal remission rates were correlated with higher MPA-AUC, with thresholds of 29.81 and 30.63 μg·h·mL-1 at 6 months and 12 months, respectively. Furthermore, the thresholds for maintaining the hypoactive state of LN were 30.96 and 31.19 μg·h·mL-1at 6 months and 12 months, respectively. Patients reaching target thresholds for MPA-AUC achieved renal response or stable disease earlier. In addition, the MPA-AUC threshold for decreasing MMF-related adverse reactions was 50.80 μg·h·mL-1. Conclusion: The initial and long-term treatments of pediatric LN patients with MMF should be individualized according to the MPA-AUC, and the recommended MPA exposure is 31.19-50.80 μg·h·mL-1.
Estimation Of Optimal Minimum Dosage Of Mycophenolate Mofetil In Children With Various Glomerular Diseases

Zhihong Lu,Haidong Fu,Lingfei Huang,Jingjing Wang,Caiyun Wang,Jianhua Mao

2018-01-01

Abstract:Background: Mycophenolate mofetil (MMF), a common immunosuppressant and a 2-ethyl ester derivative of mycophenolic acid (MPA),has exerted therapeutic efficacy in several kidney diseases. Here, we aimed to investigate the variation of MMF exposure in children with different glomerular diseases and estimate the optimal minimum dosage of MMF. Materials & methods: The serum MPA, the active compound of MMF, was measured in 57 children with primary nephrotic syndrome, Henoch Schonlein purpura nephritis, primary IgA nephropathy, or lupus nephritis. The MPA area under the curve over a 12 hour period (MPA-AUC(0-12h)) was calculated and its associations with the patients' clinical features were analyzed. Receiver operating characteristic curves were performed to explore the optimal minimum MMF dosage. Results: The average of MPA-AUC(0-12h) was 36.22 (14.38-91.47) mu g.h/mL. MAP-AUC(0-12h) of 39/57 patients was more than the target value (30 mu g.h/mL). The dose-normalized MPA-AUC(0-12) h was associated with plasma albumin but not with other clinical features. The ROC curves analyses indicated that area under the curve (AUC) in PNS was small (0.560) with a low sensitivity (28.6%) when evaluating the optimal minimum MMF dosage. In patients with HSPN, LN, or IgAN, the AUC was 0.829 with 64.0% sensitivity and 100% specificity and an optimal minimum MMF dosage of 588.2 mg/m(2) was obtained. Conclusions: MPA-AUC(0-12h) in PNS varied drastically in regard of MMF dose and should be monitored timely to adjust the MMF dosage while 588.2 mg/m(2) might be used as an optimal minimum dosage of MMF in children with LN, HSPN, or IgAN.

Model-informed dose optimization of mycophenolic acid in pediatric kidney transplant patients

Population pharmacokinetics of mycophenolic acid and dose optimisation in adult Chinese kidney transplant recipients

Pharmacokinetics of Mycophenolic Acid in Chinese Kidney Transplant Patients

Pharmacokinetics Study of Mycophenolate Mofetil in Renal Transplantation Patients

Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant

Population pharmacokinetic and dose optimization of mycophenolic acid in children with anti-neutrophilic cytoplasmic antibody-associated nephritis

Cystatin C and myeloperoxidase based mycophenolic acid dosage optimization in pediatric anti-neutrophilic cytoplasmic antibody-associated nephritis

Population Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Children after Renal Transplantation and Initial Dosage Recommendation Based on Body Surface Area.

Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients

Pk/Pd Study Of Mycophenolate Mofetil In Children With Systemic Lupus Erythematosus To Inform Model-Based Precision Dosing

Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients

Mycophenolic Acid Exposure Prediction Using Machine Learning

Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients

Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co‐treated with tacrolimus: A population analysis

Population pharmacokinetics and dosing regimen optimisation of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients.

An integrated sampling strategy for therapeutic mycophenolic acid monitoring in lung transplant recipients

245.5: Efficacy and Safety of an Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplant Recipients in China: A Prospective Cohort Study

Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools

Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study

Estimation Of Optimal Minimum Dosage Of Mycophenolate Mofetil In Children With Various Glomerular Diseases